<SEC-DOCUMENT>0001104659-24-010200.txt : 20240205
<SEC-HEADER>0001104659-24-010200.hdr.sgml : 20240205
<ACCEPTANCE-DATETIME>20240202175526
ACCESSION NUMBER:		0001104659-24-010200
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240205
DATE AS OF CHANGE:		20240202

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aprea Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001781983
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-276702
		FILM NUMBER:		24593145

	BUSINESS ADDRESS:	
		STREET 1:		3805 OLD EASTON ROAD
		CITY:			DOYLESTOWN
		STATE:			PA
		ZIP:			18902
		BUSINESS PHONE:		617-463-9385

	MAIL ADDRESS:	
		STREET 1:		3805 OLD EASTON ROAD
		CITY:			DOYLESTOWN
		STATE:			PA
		ZIP:			18902
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>tm244107-4_424b3.htm
<DESCRIPTION>424B3
<TEXT>
<html>
  <head>
    <title>tm244107-4_424b3 - none - 2.9375016s</title>
  </head>
  <body style="margin-left:auto;margin-right:auto;width:595.31pt;">
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:right; width:456pt; line-height:10pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#8202;Filed Pursuant to Rule 424(b)(3)</font>&#8203;</div>
        <div style="text-align:right; width:456pt; line-height:10pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#8202;Registration Statement No. 333-276702</font>&#8203;</div>
        <div style="margin-top:10.91pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Up to $1,000,000</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="lg_apreatherapeutics-4c.jpg" alt="[MISSING IMAGE: lg_apreatherapeutics-4c.jpg]" height="93" width="418" >
        </div>
        <div style="margin-top:15.7pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Common Stock</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have entered into an At The Market Offering Agreement (the &#8220;sales agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;) relating to shares of our common stock, par value $0.001 per share, offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $1,000,000 from time to time through Wainwright acting as our agent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our common stock is listed on The Nasdaq Capital Market under the symbol &#8220;APRE&#8221;. On February&#160;1, 2024, the last reported sale price of our common stock on The Nasdaq Capital Market was $5.70 per share. </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sales of our common stock, if any, under this this prospectus supplement and the accompanying prospectus will be made in sales deemed to be &#8220;at the market offerings&#8221; as defined in Rule&#160;415 promulgated under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Wainwright is not required to sell any specific amount of securities, but will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Wainwright and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The compensation to Wainwright for sales of common stock sold pursuant to the sales agreement will be an amount equal to 3% of the gross proceeds of any shares of common stock sold under the sales agreement. In connection with the sale of the common stock on our behalf, Wainwright will be deemed to be an &#8220;underwriter&#8221; within the meaning of the Securities Act and the compensation of Wainwright will be deemed to be underwriting commissions or discounts. See &#8220;Plan of Distribution&#8221; beginning on page S-15 for additional information regarding the compensation to be paid to Wainwright. We have also agreed to provide indemnification and contribution to Wainwright with respect to certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of January&#160;25, 2024, the aggregate market value of our common stock held by our non-affiliates pursuant to General Instruction I.B.6 of Form S-3, or public float, was $19,685,702, based on 3,164,904 shares of outstanding common stock held by non-affiliates as of such date and a price of $6.22 per share, which was the last reported sale price of our common stock on the Nasdaq Capital Market on January&#160;9, 2024. We have offered or sold $5,521,926 of securities pursuant to General Instruction I.B.6 of Form S-3 during the prior 12 calendar month period that ends on and includes the date of this prospectus (excluding this offering). Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a registered offering with a value exceeding more than one-third of our &#8220;public float&#8221; &#8203;(the market value of our common stock held by our non-affiliates) in any 12-month period so long as our public float remains below $75.0&#160;million </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; under federal securities laws and as such, have elected to comply with reduced public company reporting requirements for this prospectus and the documents incorporated by reference herein and may elect to comply with reduced public company reporting requirements in future filings. See &#8220;Summary&#8201;&#8212;&#8201;Implications of Being an Emerging Growth Company and Smaller Reporting Company.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our business and an investment in our common stock involve significant risks. These risks are described under the caption &#8220;Risk Factors&#8221; beginning on page <a href="#RIFA1">S-6</a> of this prospectus and in the documents incorporated by reference into this prospectus.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:18pt;font-weight:bold;font-size:16pt;">
          <font style="letter-spacing:-0.32pt;">H.C. Wainwright &amp; Co.</font><font style="font-weight:normal;letter-spacing:0.32pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">February&#160;2, 2024</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:386pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:205pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#ATP1"><font style="letter-spacing:0.2pt;">ABOUT THIS PROSPECTUS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#ATP1">S-1</a></font> <a href="#ATP1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#MADA"><font style="letter-spacing:0.2pt;">MARKET DATA </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#MADA">S-2</a></font> <a href="#MADA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#PRSU"><font style="letter-spacing:0.2pt;">PROSPECTUS SUMMARY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#PRSU">S-3</a></font> <a href="#PRSU"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#THOF"><font style="letter-spacing:0.2pt;">THE OFFERING </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#THOF">S-5</a></font> <a href="#THOF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#RIFA1"><font style="letter-spacing:0.2pt;">RISK FACTORS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#RIFA1">S-6</a></font> <a href="#RIFA1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#SNRFWS"><font style="letter-spacing:0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#SNRFWS">S-8</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#UOP1"><font style="letter-spacing:0.2pt;">USE OF PROCEEDS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#UOP1">S-10</a></font> <a href="#UOP1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#DIL"><font style="letter-spacing:0.2pt;">DILUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#DIL">S-11</a></font> <a href="#DIL"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#DOCS1"><font style="letter-spacing:0.2pt;">DESCRIPTION OF CAPITAL STOCK </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#DOCS1">S-12</a></font> <a href="#DOCS1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#POD1"><font style="letter-spacing:0.2pt;">PLAN OF DISTRIBUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#POD1">S-15</a></font> <a href="#POD1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#LEMA1"><font style="letter-spacing:0.2pt;">LEGAL MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#LEMA1">S-16</a></font> <a href="#LEMA1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#EXP1"><font style="letter-spacing:0.2pt;">EXPERTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#EXP1">S-16</a></font> <a href="#EXP1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#WYCF1"><font style="letter-spacing:0.2pt;">WHERE YOU CAN FIND MORE INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#WYCF1">S-16</a></font> <a href="#WYCF1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#IOCI"><font style="letter-spacing:0.2pt;">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#IOCI">S-17</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="ATP1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:52pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ABOUT THIS PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus is part of a shelf registration statement on Form S-3 that we filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;). Under the shelf registration process, we may offer shares of our common stock having an aggregate offering price of up to $1,000,000 from time to time under this prospectus and the accompanying base prospectus at prices and on terms to be determined by market conditions at the time of the offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We provide information to you about this offering of shares of our common stock in two separate documents that are bound together: (1)&#160;this At The Market Offering Agreement prospectus, which describes the specific details regarding this offering; and (2)&#160;the accompanying base prospectus, which provides general information, some of which may not apply to this offering. Generally, when we refer to this &#8220;prospectus,&#8221; we are referring to both documents combined. If information in this At The Market Offering Agreement prospectus is inconsistent with the accompanying base prospectus, you should rely on this prospectus. However, if any statement in one of these documents is inconsistent with a statement in another document having a later date&#8201;&#8212;&#8201;for example, a document incorporated by reference in this prospectus&#8201;&#8212;&#8201;the statement in the document having the later date modifies or supersedes the earlier statement as our business, financial condition, results of operations and prospects may have changed since the earlier dates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should rely only on the information contained in, or incorporated by reference into, this prospectus and in any free writing prospectus that we may authorize for use in connection with this offering. We have not, and Wainwright has not, authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not, and Wainwright is not, making an offer to sell or soliciting an offer to buy our securities in any jurisdiction in which an offer or solicitation is not authorized or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should assume that the information appearing in this prospectus, the documents incorporated by reference into this prospectus, and in any free writing prospectus that we may authorize for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus, the documents incorporated by reference into this prospectus, and any free writing prospectus that we may authorize for use in connection with this offering, in their entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the sections of this prospectus entitled &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation by Reference.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are offering to sell, and seeking offers to buy, shares of common stock only in jurisdictions where offers and sales are permitted. The distribution of this prospectus and the offering of the common stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the common stock and the distribution of this prospectus outside the United States. This prospectus does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In this prospectus, the terms &#8220;Aprea,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar terms refer to Aprea Therapeutics, Inc., a Delaware corporation, and its subsidiaries unless the context otherwise requires. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus and the information incorporated herein by reference include trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included or incorporated by reference in this prospectus are the property of their respective owners. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="MADA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:500pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MARKET DATA</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus and the documents incorporated by reference herein include market and industry data and forecasts concerning our business and the markets for certain cancers, including data regarding the estimated size of those markets and the incidence and prevalence of certain medical conditions, that we have derived from independent consultant reports, publicly available information, various industry, medical and general publications, other published industry sources, government data and our internal data and estimates. Independent consultant reports, industry publications and other published industry sources generally indicate that the information contained therein was obtained from sources believed to be reliable. Our internal data and estimates are based upon information obtained from trade and business organizations and other contacts in the markets in which we operate and our management&#8217;s understanding of industry conditions.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="PRSU">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">PROSPECTUS SUMMARY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">This summary highlights certain information about us, this offering and selected information contained elsewhere in or incorporated by reference into this prospectus. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in the securities covered by this prospectus. For a more complete understanding of Aprea and this offering, we encourage you to read and consider carefully the more detailed information in this prospectus, including the information incorporated by reference in this prospectus and the information included in any free writing prospectus that we have authorized for use in connection with this offering, including the information referred to under the heading &#8220;Risk Factors&#8221; in this prospectus beginning on page S-6.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We are a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. Our approach is built upon a platform of integrated discovery technologies to enrich our pipeline with novel targets in synthetic lethality and cancer treatment. Together with our expertise in small molecule drug discovery, we are applying the capabilities of our discovery platform to the development of new precision oncology therapies and the identification of patient populations most likely to benefit. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">On May&#160;16, 2022, we acquired Atrin Pharmaceuticals Inc. (&#8220;Atrin&#8221;), in accordance with the terms of the Agreement and Plan of Merger dated May&#160;16, 2022 (the &#8220;Merger Agreement&#8221;), by and among us, ATR Merger Sub I Inc., a Delaware corporation and our wholly owned subsidiary (&#8220;First Merger Sub&#8221;), ATR Merger Sub II LLC, a Delaware limited liability company and wholly owned subsidiary of Aprea (&#8220;Second Merger Sub&#8221;) and Atrin. Pursuant to the Merger Agreement, First Merger Sub merged with and into Atrin, pursuant to which Atrin was the surviving corporation and became a wholly owned subsidiary of Aprea (the &#8220;First Merger&#8221;). Immediately following the First Merger, Atrin merged with and into the second Merger Sub, pursuant to which Second Merger Sub was the surviving entity. The former Atrin business is now our business. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We believe that synthetic lethality has the potential to impact patients&#8217; lives and treatment strategies for a wide range of cancer types. When a gene in the DNA damaged response (&#8220;DDR&#8221;) pathway is damaged or fails, related genes make up for its loss of function. Our approach is to inhibit these genes, thereby specifically killing cancer cells with specific mutations. This approach is called synthetic lethality. Using synthetic lethality, our product candidates are designed to selectively kill cancer cells while minimizing the effect on normal, unmutated cells, decreasing the toxicity normally associated with cancer treatment. We aspire to become a leader in this emerging field and are establishing a pipeline of clinical and preclinical programs that we believe may have broad application to cancer treatment. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our most advanced synthetic lethality product candidate is ATRN-119, a clinical-stage small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR, a kinase that plays a critical role in DDR. ATR is one of several key regulators of the response to defective DNA replication and DNA damage, which occurs more commonly in cancer cells than in normal cells. We are enrolling patients into a Phase&#160;1/2a clinical trial to evaluate ATRN-119 under an investigational new drug application, or IND. The first four dose cohorts have been completed, and patients with advanced solid tumors having mutations in defined DDR-related genes continue to be enrolled into additional cohorts of the Phase&#160;1 dose escalation part of the trial. The primary endpoint of this Phase&#160;1 part is to evaluate the tolerability and pharmacokinetics of ATRN-119 when administered orally on a continuous, once-daily schedule. We anticipate ATRN-119 tolerability and pharmacokinetic data from Phase&#160;1 to be available in the second half of 2024. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We have several additional, wholly owned preclinical synthetic lethality programs. We are targeting WEE1, a kinase that is a key regulator of multiple phases of the cell cycle. Our lead WEE1 inhibitor product candidate is ATRN-1051, and we anticipate clearance of the IND for ATRN-1051 by the end of the first quarter of 2024. In addition, we have a preclinical research program directed at a second-generation ATR inhibitor, APR-354. Finally, we also have an early preclinical research program, which is aimed at identification of novel inhibitors of a distinct protein involved in DDR. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">In addition to development of these drugs as single agents, we are evaluating potential expansion opportunities for our product candidates through twice a day administration (BID) as well as combination </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">with other agents such as poly (ADP-ribose) polymerase inhibitors, or PARPi, where we believe a combination of therapeutic agents may enhance synthetic lethality. We are also evaluating combination opportunities within our pipeline, including research on the combination of ATRN-119 and ATRN-1051 that is supported by a Phase&#160;II SBIR grant from the National Cancer Institute. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Prior to the acquisition of Atrin, we were engaged in the clinical development of cancer therapeutics that reactivate the mutant p53 tumor suppressor protein. Our lead product candidate was APR-246, or eprenetapopt. Following our failed pivotal Phase&#160;3 trial in December&#160;2020, we engaged in a thorough evaluation of strategic options leading to the acquisition of Atrin and shifting our focus to the Atrin assets. We do not currently have any ongoing preclinical studies or clinical trials involving our reactivators of mutant p53 and our primary focus is on the discovery and development of molecules targeting DDR pathways in oncology through synthetic lethality. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We have assembled a team with extensive experience in the discovery, development and commercialization of oncology drugs to support our mission of developing novel synthetic lethality-based cancer therapeutics. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Implications of Being an Emerging Growth Company and Smaller Reporting Company</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We may take advantage of certain exemptions from various public company reporting requirements, including not being required to have our internal control over financial reporting audited by our independent registered public accounting firm under Section&#160;404 of the Sarbanes-Oxley Act of 2002 reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute payments. We may take advantage of these exemptions until December&#160;31, 2024 or until we are no longer an &#8220;emerging growth company,&#8221; whichever is earlier. We will cease to be an emerging growth company prior to the end of such period if certain earlier events occur, including if we become a &#8220;large accelerated filer&#8221; as defined in Rule&#160;12b-2 under the Securities Exchange Act of 1934, as amended, or Exchange Act, our annual gross revenues exceed $1.235&#160;billion or we issue more than $1.0&#160;billion of non-convertible debt in any three-year period. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of accounting standards that have different effective dates for public and private companies until those standards would otherwise apply to private companies. We have not elected to avail ourselves of this exemption and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not &#8220;emerging growth companies.&#8221; </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We are also a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and non-voting common stock held by non-affiliates is less than $250.0&#160;million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0&#160;million measured on the last business day of our second fiscal quarter. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Corporate Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our principal executive offices are located at 3805 Old Easton Road, Doylestown, PA 18902, and our telephone number is (617) 463-9385. Our website address is www.aprea.com. The information contained on or accessible through our website is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our website as part of this prospectus or in deciding whether to purchase our common stock. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our filings with the SEC are posted on our website at www.aprea.com. The information found on or accessible through our website is not part of this or any other report we file with or furnish to the SEC. The public can also obtain copies of these filings by accessing the SEC&#8217;s website at http://www.sec.gov. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="THOF">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">The Offering</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:12pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Common stock offered by us</font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Shares having an aggregate offering price of up to $1,000,000. </font>
          </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:12pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Common stock to be outstanding after this offering</font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Up to 3,912,111 shares, assuming the sale of $1,000,000 of shares at a sales price of $5.70 per share, which was the last reported sale price on The Nasdaq Capital Market on February&#160;1, 2024. The actual number of shares issued and outstanding will vary depending on the sales price under this offering. </font>
          </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:12pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Manner of offering</font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#8220;At-the-market&#8221; offering that may be made from time to time through our sales agent, Wainwright. See &#8220;Plan of Distribution&#8221; on page S-15 of this prospectus. </font>
          </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:12pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Use of proceeds</font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our management will retain broad discretion regarding the allocation and use of the net proceeds from this offering. We currently intend to use the net proceeds from this offering, if any, for general corporate purposes, including for preclinical studies and clinical trials and the advancement of our product candidates. See &#8220;Use of Proceeds&#8221; on page S-10 of this prospectus. </font>
          </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:12pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">NASDAQ Capital Market symbol</font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#8220;APRE&#8221; </font>
          </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:12pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Risk factors</font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Investing in our securities involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page S-6 of this prospectus and the other information included in, or incorporated by reference into, this prospectus for a discussion of certain factors that you should carefully consider before deciding to invest in shares of our common stock. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The number of shares of common stock shown above to be outstanding immediately following this offering is based on 3,736,673 shares outstanding as of September&#160;30, 2023 and excludes: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">28,112 shares of common stock issuable upon conversion of our outstanding Series&#160;A Preferred Stock. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">This prospectus reflects and assumes no exercise of outstanding options or warrants.</font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="RIFA1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RISK FACTORS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Investing in our securities involves risk. You should carefully consider the specific risks discussed or incorporated by reference into the applicable prospectus supplement, together with all the other information contained in the prospectus or incorporated by reference into this prospectus and the applicable prospectus supplement. You should also consider the risks, uncertainties and assumptions discussed under the caption &#8220;Risk Factors&#8221; included in our <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1781983/000155837023005126/apre-20221231x10k.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2022</a> and in our Quarterly Reports on Form 10-Q for the periods ended <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1781983/000155837023009887/apre-20230331x10q.htm">March&#160;31</a>, <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1781983/000155837023014405/apre-20230630x10q.htm">June&#160;30</a> and <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1781983/000155837023018572/apre-20230930x10q.htm">September&#160;30, 2023</a>, and in subsequent filings, which are incorporated by reference into this prospectus. These risk factors may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future or by a prospectus supplement relating to a particular offering of our securities. These risks and uncertainties are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us, or that we currently view as immaterial, may also impair our business. If any of the risks or uncertainties described in our SEC filings or any prospectus supplement or any additional risks and uncertainties actually occur, our business, financial condition and results of operations could be materially and adversely affected. In that case, the trading price of our securities could decline and you might lose all or part of your investment.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:10.32pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Relating to this Offering</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Management will have broad discretion as to the use of the proceeds from this offering and may not use the proceeds effectively</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.42pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We cannot specify with certainty all of the particular uses of the net proceeds of this offering. Our management will have significant flexibility in applying the net proceeds from this offering, and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are being used appropriately. Investors may not agree with our decisions on the use of proceeds of this offering, and our use of the proceeds may not yield any return on your investment. Because of the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Our management may use the net proceeds for purposes that may not improve our financial condition or market value. Our failure to apply the net proceeds of this offering effectively could impair our ability to pursue our growth strategy or could require us to raise additional capital. Pending their use, we intend to invest the net proceeds from the offering in investment-grade, interest-bearing instruments, such as money market accounts, certificates of deposit, commercial paper and guaranteed obligations of the U.S. government. These investments may not yield a favorable return to our stockholders. </font>
        </div>
        <div style="margin-top:7.41pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Future sales of substantial amounts of our common stock, or the possibility that such sales could occur, could adversely affect the market price of our common stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.31pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may issue up to $1.0&#160;million of shares of common stock from time to time in this offering. The issuance from time to time of shares in this offering, as well as our ability to issue such shares in this offering, could have the effect of depressing the market price or increasing the market price volatility of our common stock. </font>
        </div>
        <div style="margin-top:10.22pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">It is not possible to predict the actual number of shares we will sell under the sales agreement, or the gross proceeds resulting from those sales.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to certain limitations in the sales agreement and compliance with applicable law, we have the discretion to deliver a placement notice to the sales agent at any time throughout the term of the sales agreement. The number of shares that are sold through the sales agent after delivering a placement notice will fluctuate based on a number of factors, including the market price of the common stock during the sales period, the limits we set with the sales agent in any applicable placement notice, and the demand for our common stock during the sales period. Because the price per share of each share sold will fluctuate during the sales period, it is not currently possible to predict the number of shares that will be sold or the gross proceeds to be raised in connection with those sales. </font>
        </div>
        <div style="margin-top:10.22pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The common stock offered hereby will be sold in &#8220;at the market offerings,&#8221; and investors who buy shares at different times will likely pay different prices.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Investors who purchase shares in this offering at different times will likely pay different prices, and so they may experience different levels of dilution and different outcomes in their investment results. We will </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:48pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold in this offering. In addition, there is no minimum or maximum sales price for shares to be sold in this offering. Investors may experience a decline in the value of the shares they purchase in this offering as a result of sales made at prices lower than the prices they paid. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">You may experience immediate and substantial dilution</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the offering price per share you pay in this offering exceeds the net tangible book value per share of our common stock, you will be immediately diluted to the extent of the difference between the amount you pay per share and the as adjusted net tangible book value per share of our common stock after giving effect to this offering. Assuming we sell an aggregate amount of $1.0&#160;million in this offering at an assumed public offering price of $5.70 per share, the closing price per share of our common stock on The Nasdaq Capital Market on February&#160;1, 2024, and after deducting commissions and estimated aggregate offering expenses payable by us, you would experience immediate dilution in net tangible book value of $0.31 per share, representing a difference between the assumed public offering price per share and our as adjusted net tangible book value per share after this offering. To the extent that outstanding options are exercised or outstanding restricted stock&#160;units vest and settle, investors purchasing our common stock in this offering may experience further dilution. See the section entitled &#8220;Dilution&#8221; for a more detailed illustration of the dilution you may incur if you participate in this offering. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">You may experience future dilution as a result of future equity offerings.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock. We may not be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock or other securities convertible into or exchangeable for our common stock in future transactions may be higher or lower than the price per share in this offering. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If securities or industry analysts fail to continue publishing research about our business, if they change their recommendations adversely or if our results of operations do not meet their expectations, our stock price and trading volume could decline.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. In addition, it is likely that in some future period our operating results will be below the expectations of securities analysts or investors. If one or more of the analysts who cover us downgrade our stock, or if our results of operations do not meet their expectations, our stock price could decline. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Because we do not intend to declare cash dividends on our shares of common stock in the foreseeable future, stockholders must rely on appreciation of the value of our common stock for any return on their investment.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends in the foreseeable future. In addition, the terms of any existing or future debt agreements may preclude us from paying dividends. As a result, we expect that only appreciation of the price of our common stock, if any, will provide a return to investors in this offering for the foreseeable future. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="SNRFWS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus includes and incorporates by reference &#8220;forward-looking statements&#8221; within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and releases issued by the SEC and within the meaning of Section&#160;27A of the Securities Act, and Section&#160;21E of the Exchange Act. All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of this prospectus. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;contemplate,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;potential,&#8221; &#8220;ongoing,&#8221; &#8220;goal,&#8221; or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to continue to operate as an integrated company subsequent to our acquisition of Atrin Pharmaceuticals Inc.; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">estimates of our expenses, capital requirements and our needs for additional financing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">business interruptions, including delays in enrollment, patient follow-up and data collection of clinical trials, resulting from a public health emergency or pandemic; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the prospects of our product candidates, all of which are still in development; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">outcome and results of ongoing or future preclinical studies and clinical trials of our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our expectations regarding our ability to identify, discover or acquire additional suitable product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the design of our ongoing and planned clinical trials, including the sample size, trial duration, endpoint definition, event rate assumptions and eligibility criteria; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to enroll patients in clinical trials, to timely and successfully complete those trials and to receive necessary regulatory approvals; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our expectations regarding the timing of initiation of data readout from our clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">market acceptance or commercial success of any product candidate we develop and the degree of acceptance among physicians, patients, patient advocacy groups, healthcare payors and the medical community; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our expectations regarding competition, potential market size, the size of the patient populations for our product candidates, if approved for commercial use, and market acceptance; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to obtain regulatory approval of our product candidates, and any restrictions, limitations and/or warnings in their labels, if approved; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">potential claims relating to our intellectual property and third-party intellectual property; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the duration of our intellectual property estate that will provide protection for our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">developments relating to our competitors and our industry; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our sales, marketing or distribution capabilities and our ability to commercialize our product candidates, if we obtain regulatory approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">current and future agreements with third parties in connection with conducting clinical trials, as well as the manufacturing of our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our expectations regarding the ability of our current contract manufacturing partners to produce our product candidates in the quantities and timeframe that we will require; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our expectations regarding our future costs of goods; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to attract, retain and motivate key personnel and increase the size of our organization; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:282pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to establish collaborations in lieu of obtaining additional financing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the impact of government laws and regulations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our financial performance; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act or a smaller reporting company under the Exchange Act. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. In evaluating such forward-looking statements, you should specifically consider various factors that may cause actual results to differ materially from current expectations, including the risks outlined under the heading &#8220;Risk Factors&#8221; contained in this prospectus and any related free writing prospectus, and in any other documents incorporated herein or therein. Any forward-looking statement in this prospectus reflects our current view with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus and the documents incorporated by reference, may also contain estimates, projections and other information concerning our industry, our business and the markets for certain drugs, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained these industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which these data are derived. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="UOP1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:400pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">USE OF PROCEEDS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may issue and sell shares of our common stock having aggregate sales proceeds of up to $1,000,000 from time to time. The amount of proceeds from this offering will depend upon the number of shares of our common stock sold and the market price at which they are sold. Because there is no minimum offering amount required as a condition of this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. There can be no assurance that we will be able to sell any shares under, or fully utilize, the sales agreement with Wainwright as a source of financing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will retain broad discretion over the use of the net proceeds from the sale of the securities offered hereby. We currently intend to use the net proceeds from this offering, if any, for general corporate purposes, including for preclinical studies and clinical trials and the advancement of our product candidates. The amount and timing of these expenditures will depend on a number of factors, such as the timing, scope, progress and results of our research and development efforts, the timing and progress of any partnership efforts, and the competitive environment for our product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of the date of this prospectus, we cannot specify with certainty all of the particular uses for the net proceeds to us from this offering, if any. As a result, our management will have broad discretion regarding the timing and application of the net proceeds from this offering. Pending the application of the net proceeds, we intend to invest the net proceeds in short-term, investment grade, interest-bearing securities. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="DIL">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:206pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DILUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If you invest in our common stock, you will experience dilution to the extent of the difference between the price per share you pay in this offering and the net tangible book value per share of our common stock immediately after this offering. Our net tangible book value as of September&#160;30, 2023 was approximately $20.3&#160;million or $5.42 per share of our common stock. Net tangible book value per share as of September&#160;30, 2023 is equal to our total tangible assets minus total liabilities and the carrying value of Series&#160;A convertible preferred stock, all divided by the number of shares of common stock outstanding as of September&#160;30, 2023. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">After giving effect to the sale of $1,000,000 of shares of our common stock in this offering at an assumed offering price of $5.70 per share, the last reported sale price of our common stock on The Nasdaq Capital Market on February&#160;1, 2024, and after deducting estimated offering commissions and expenses payable by us, our as adjusted net tangible book value would have been approximately $20.9 million or $5.39 per share of common stock, as of September&#160;30, 2023. This represents an immediate decrease in net tangible book value of approximately $0.03 per share to existing stockholders and an immediate dilution of approximately $0.31 per share to investors in this offering. The following table illustrates this calculation on a per share basis. </font>
        </div>
        <table style="width:456pt;height:83pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:386.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Assumed public offering price per share </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">5.70</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:386.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net tangible book value per share as of September&#160;30, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5.42</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:386.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Decrease in net tangible book value per share attributable to this offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">0.03</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:1.917pt 0pt 1.833pt 0pt; width:386.59pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">As adjusted net tangible book value per share as of September&#160;30, 2023, after giving effect to this offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">5.39 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.833pt 0pt; width:386.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Dilution per share to new investors purchasing shares in this offering </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.833pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">0.31</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The number of shares of common stock shown above to be outstanding immediately following this offering is based on 3,736,673 shares outstanding as of September&#160;30, 2023 and excludes: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">28,112 shares of common stock issuable upon conversion of our outstanding Series&#160;A Preferred Stock. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The above illustration of dilution per share to investors participating in this offering assumes no exercise of outstanding options or warrants to purchase our common stock. The exercise of outstanding options or warrants having an exercise price per share that is less than the offering price per share in this offering will increase dilution to investors in this offering.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="DOCS1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF CAPITAL STOCK</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The following description is a general summary of the terms of the shares of common stock or shares of preferred stock that we may issue. The description below and in any prospectus supplement does not include all of the terms of the shares of common stock or shares of preferred stock and should be read together with our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, copies of which have been filed previously with the SEC. For more information on how you can obtain copies of our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, see &#8220;Where You Can Find More Information.&#8221;</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our charter authorizes us to issue up to 400,000,000 shares of common stock, par value $0.001 per share, and 40,000,000 shares of preferred stock, par value $0.001 per share. The following summary sets forth some of the general terms of our common stock. Because this is a summary, it does not contain all of the information that may be important to you. For a more detailed description of our common stock, you should read our amended and restated certificate of incorporation and the amended and restated bylaws, each of which is an exhibit to our Annual Report on Form 10-K to which this summary is also an exhibit, and the applicable provisions of the Delaware General Corporation Law (the &#8220;DGCL&#8221;). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Common stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of November&#160;9, 2023, we had outstanding 3,736,673 shares of common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Voting Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders will be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Other matters shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter, except as otherwise disclosed below. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Dividends</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of outstanding preferred stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Liquidation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately all assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption or conversion rights. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Rights and Preferences</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Preferred stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors is authorized to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. You should refer to the applicable certificate of designation for complete information regarding a series of preferred stock to be issued under this prospectus and the applicable prospectus supplement. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock. As of September&#160;30, 2023, there were 56,227 shares of Series&#160;A Preferred Stock outstanding. We have no present plans to issue any additional shares of preferred stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Anti-Takeover effects of Delaware law and our charter and bylaws</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Delaware law, our certificate of incorporation and our bylaws contain provisions that could have the effect of delaying, deferring or discouraging another party from acquiring control of us. These provisions, which are summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Staggered board; removal of directors</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our certificate of incorporation and bylaws divides our board of directors into three classes with staggered three-year terms. In addition, a director may only be removed for cause and only by the affirmative vote of the holders of a majority of the votes that all of our stockholders would be entitled to cast in an annual election of directors. Any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, will only be able to be filled by vote of a majority of our directors then in office. The classification of our board of directors and the limitations on the removal of directors and filling of vacancies could make it more difficult for a third party to acquire, or discourage a third party from seeking to acquire, control of our company. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Stockholder action by written consent; special meetings</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our certificate of incorporation provides that any action required or permitted to be taken by our stockholders must be effected at a duly called annual or special meeting of such holders and may not be effected by any consent in writing by such holders. Our certificate of incorporation and bylaws also provide that, except as otherwise required by law, special meetings of our stockholders can only be called by our chairman of the board, our Chief Executive Officer or our board of directors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Advance notice requirements for stockholder proposals</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of stockholders, including proposed nominations of persons for election to our board of directors. Stockholders at an annual meeting are only able to consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors or by a stockholder of record on the record date for the meeting who is entitled to vote at the meeting and who has delivered timely written notice in proper form to our secretary of the stockholder&#8217;s intention to bring such business before the meeting. These provisions could have the effect of delaying until the next stockholder meeting stockholder actions that are favored by the holders of a majority of our outstanding voting securities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Delaware business combination statute</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are subject to Section&#160;203 of the DGCL. Subject to certain exceptions, Section&#160;203 prevents a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with any &#8220;interested stockholder&#8221; for three&#160;years following the date that the person became an interested stockholder, unless the interested stockholder attained such status with the approval of our board of directors or unless the business combination is approved in a prescribed manner. A &#8220;business combination&#8221; includes, among other things, a merger or consolidation involving us and the &#8220;interested stockholder&#8221; and the sale of more than 10% of our assets. In general, an &#8220;interested stockholder&#8221; is any entity or person beneficially owning 15% or more of our outstanding voting stock and any entity or person affiliated with or controlling or controlled by such entity or person. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:84pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Amendment of certificate of incorporation and bylaws</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#8217;s certificate of incorporation or bylaws, unless a corporation&#8217;s certificate of incorporation or bylaws, as the case may be, requires a greater&#160;percentage. Our bylaws may be amended or repealed by a majority vote of our board of directors or by the affirmative vote of the holders of at least 75% of the votes that all of our stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders of at least 75% of the votes that all of our stockholders would be entitled to cast in any annual election of directors is required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our certificate of incorporation described above under &#8220;Staggered board; removal of directors&#8221; and &#8220;Stockholder action by written consent; special meetings.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Exclusive forum selection</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our certificate of incorporation provides, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the Court of Chancery of the State of Delaware (or if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for (1)&#160;any derivative action or proceeding brought on behalf of our company under Delaware law, (2)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or employees to our company or our stockholders, (3)&#160;any action asserting a claim against our company arising pursuant to any provision of the DGCL or our certificate of incorporation or bylaws, (4)&#160;any action asserting a claim against our company governed by the internal affairs doctrine or (5)&#160;any other action asserting an &#8220;internal corporate claim,&#8221; as defined in Section&#160;115 of the DGCL. These exclusive-forum provisions do not currently apply to claims under the Securities Act of 1933, as amended, or the Exchange Act. Any person or entity purchasing or otherwise acquiring any interest in our securities shall be deemed to have notice of and consented to this provision. Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against us or our directors and officers. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Listing on The Nasdaq Capital Market</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our common stock is listed on The Nasdaq Capital Market under the symbol &#8220;APRE.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Authorized but unissued shares</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval, subject to any limitations imposed by the listing requirements of The Nasdaq Capital Market. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could make it more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Transfer agent and registrar</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. The transfer agent and registrar&#8217;s address is 150 Royall St., Canton, MA 02021.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="POD1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PLAN OF DISTRIBUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have entered into a sales agreement with H.C. Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;) under which we may issue and sell from time to time up to $1,000,000 of our common stock through Wainwright as our sales agent. Sales of our common stock, if any, will be made at market prices by any method that is deemed to be an &#8220;at the market&#8221; offering as defined in Rule&#160;415 under the Securities Act, including sales made directly on The Nasdaq Capital Market or any other existing trading market in the United States for our common stock, sales made to or through a market maker other than on an exchange or otherwise, directly to Wainwright as principal, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices and/or in any other method permitted by law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Wainwright will offer our common stock subject to the terms and conditions of the sales agreement on a daily basis or as otherwise agreed upon by us and Wainwright. We will designate the maximum amount of common stock to be sold through Wainwright on a daily basis or otherwise determine such maximum amount together with Wainwright. Subject to the terms and conditions of the sales agreement, Wainwright will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell on our behalf all of the shares of common stock requested to be sold by us. We may instruct Wainwright not to sell common stock if the sales cannot be effected at or above the price designated by us in any such instruction. Wainwright or we may suspend the offering of our common stock being made through Wainwright under the sales agreement upon proper notice to the other party. We or Wainwright may suspend the offering of the common stock being made through Wainwright under the sales agreement upon proper notice to the other party. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The aggregate compensation payable to Wainwright as sales agent is equal to 3.0% of the gross sales price of the shares sold through it pursuant to the sales agreement. Pursuant to the terms of the sales agreement, we agreed to reimburse Wainwright for the reasonable fees and expenses of its legal counsel incurred in connection with entering into the sales agreement in an amount not to exceed $50,000 in the aggregate, in addition to up to $2,500 per due diligence update session for Wainwright&#8217;s counsel&#8217;s fees. We estimate that the total expenses of the offering payable by us, excluding commissions payable to Wainwright under the sales agreement, will be approximately $125,000. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The remaining sales proceeds, after deducting any expenses payable by us and any transaction fees imposed by any governmental, regulatory, or self-regulatory organization in connection with the sales, will equal our net proceeds for the sale of such common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Wainwright will provide written confirmation to us following the close of trading on The Nasdaq Capital Market on each day in which common stock is sold through it as sales agent under the sales agreement. Each confirmation will include the number of shares of common stock sold through it as sales agent on that day, the volume weighted average price of the shares sold, the&#160;percentage of the daily trading volume and the net proceeds to us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the extent any sales are made, we will report at least quarterly the number of shares of common stock sold through Wainwright under the sales agreement, the net proceeds to us and the compensation paid by us to Wainwright in connection with the sales of common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Settlement for sales of common stock will occur on the second business day or such shorter settlement cycle as may be in effect under Exchange Act Rule&#160;15c6-1 from time to time, following the date on which any sales are made, or on some other date that is agreed upon by us and Wainwright in connection with a particular transaction, in return for payment of the net proceeds to us. Sales of our common stock as contemplated in this prospectus supplement and the accompanying prospectus will be settled through the facilities of The Depository Trust Company or by such other means as we and Wainwright may agree upon. There is no arrangement for funds to be received in an escrow, trust or similar arrangement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with the sales of our common stock on our behalf, Wainwright may be deemed to be an &#8220;underwriter&#8221; within the meaning of the Securities Act, and the compensation paid to Wainwright may be deemed to be underwriting commissions or discounts. We have agreed in the sales agreement to provide indemnification and contribution to Wainwright against certain liabilities, including liabilities under the Securities Act. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="LEMA1">&#8203;</a><a name="EXP1">&#8203;</a><a name="WYCF1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our common stock is listed on The Nasdaq Capital Market and trades under the symbol &#8220;APRE.&#8221; The transfer agent of our common stock is Computershare. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the extent required by Regulation&#160;M, Wainwright will not engage in any market making activities involving our shares of common stock while the offering is ongoing under this prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Wainwright and/or its affiliates have provided, and may in the future provide, various investment banking and other financial services for us for which services they have received and, may in the future receive, customary fees. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, in the ordinary course of its business activities, Wainwright and its affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities may involve securities and/or instruments of ours or our affiliates. Wainwright and its affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LEGAL MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Certain legal matters in connection with the securities offered hereby will be passed upon for us by DLA Piper LLP (US), Philadelphia, Pennsylvania. Ellenoff Grossman &amp; Schole LLP, New York, New&#160;York, is counsel for Wainwright in connection with this offering. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXPERTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Ernst &amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1781983/000155837023005126/apre-20221231x10k.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2022</a>, as set forth in their report, which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst &amp; Young LLP&#8217;s report, given on their authority as experts in accounting and auditing. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">WHERE YOU CAN FIND MORE INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have filed with the SEC a registration statement on Form S-3 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), with respect to the securities offered by this prospectus. This prospectus does not contain all of the information set forth in the registration statement, of which it is a part, and its exhibits and schedules in accordance with SEC rules and regulations. For further information with respect to us and the securities being offered by this prospectus, you should read the registration statement, including its exhibits and schedules. Statements contained in this prospectus, including documents that we have incorporated by reference, as to the contents of any contract or other document referred to are not necessarily complete, and, with respect to any contract or other document filed as an exhibit to the registration statement or any other such document, each such statement is qualified in all respects by reference to the corresponding exhibit. You should review the complete contract or other document to evaluate these statements. You may obtain copies of the registration statement and its exhibits via the SEC&#8217;s website at http://www.sec.gov. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are subject to the information and periodic reporting requirements of the Exchange Act, and we file annual, quarterly and current reports, proxy statements and other documents with the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information regarding issuers, including us, that file electronically with the SEC. You may obtain documents that we file with the SEC at http://www.sec.gov. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We also make these documents available on our website at </font><font style="font-style:italic;letter-spacing:0.2pt;">www.aprea.com</font><font style="letter-spacing:0.2pt;">. Our website and the information contained or accessible through our website is not incorporated by reference in this prospectus, and you should not consider it part of this prospectus. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="IOCI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">SEC rules permit us to incorporate information by reference in this prospectus and any applicable prospectus supplement. This means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is considered to be part of this prospectus and any applicable prospectus supplement, except for information superseded by information contained in this prospectus or any applicable prospectus supplement itself or in any subsequently filed incorporated document. This prospectus and any applicable prospectus supplement incorporate by reference the documents set forth below that we have previously filed with the SEC, other than information in such documents that is deemed to be furnished and not filed. These documents contain important information about us and our business and financial condition. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;letter-spacing:0.2pt;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;letter-spacing:0.2pt;">
          <!--blacklining:none;-->
          <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1781983/000155837023005126/apre-20221231x10k.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC on March&#160;30, 2023</a><font style="letter-spacing:0.2pt;"> </font><a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1781983/000155837023007284/apre-20221231x10ka.htm">(as amended by Amendment No. 1 to our Annual Report on Form 10-K filed with the SEC on April&#160;28, 2023)</a><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;"><a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1781983/000155837023009887/apre-20230331x10q.htm">Quarterly Report on Form 10-Q for the period ended March&#160;31, 2023, filed with the SEC on May&#160;15, 2023;</a> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;"><a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1781983/000155837023014405/apre-20230630x10q.htm">Quarterly Report on Form 10-Q for the period ended June&#160;30, 2023, filed with the SEC on August&#160;10, 2023;</a> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;"><a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1781983/000155837022017205/apre-20220930x10q.htm">Quarterly Report on Form 10-Q for the period ended September&#160;30, 2023, filed with the SEC on November&#160;9, 2023;</a> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Current Reports on Form 8-K, filed with the SEC on <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1781983/000110465923008020/tm234708d1_8k.htm">January&#160;30, 2023</a>, <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1781983/000110465923018997/tm236225d1_8k.htm">February&#160;13, 2023</a>, <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1781983/000110465923025392/tm237532d3_8k.htm">February&#160;24, 2023</a>, <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1781983/000110465923039155/tm2310933d1_8k.htm">March&#160;30, 2023</a>, <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1781983/000110465923046719/tm2312947d1_8k.htm">April&#160;18, 2023</a>, <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1781983/000155837023008389/apre-20230505x8k.htm">May&#160;8, 2023</a>, <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1781983/000155837023009864/apre-20230515x8k.htm">May&#160;15, 2023</a> (other than the information furnished pursuant to Item&#160;2.02), <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1781983/000110465923078072/tm2320610d1_8k.htm">July&#160;5, 2023</a>, <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1781983/000155837023014403/apre-20230810x8k.htm">August&#160;10, 2023</a> (other than the information furnished pursuant to Item&#160;2.02), <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1781983/000155837023015237/apre-20230823x8k.htm">August&#160;24, 2023</a>, <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1781983/000155837023015621/apre-20230911x8k.htm">September&#160;11, 2023</a>, <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1781983/000155837023016426/apre-20231013x8k.htm">October&#160;13, 2023</a>, <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1781983/000155837023016468/apre-20231016x8k.htm">October&#160;16, 2023</a>, <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1781983/000155837023018581/apre-20231109x8k.htm">November&#160;9, 2023</a> (other than the information furnished pursuant to Item&#160;2.02), <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1781983/000155837024000060/apre-20240104x8k.htm">January&#160;4, 2024</a> and February&#160;2, 2024; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;"><a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1781983/000110465919052022/a19-12476_98a12b.htm">the description of our Common Stock contained in our Registration Statement on Form 8/A, dated September&#160;30, 2019, including any amendments or reports filed for the purpose of updating such description. </a></font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All documents that we file (but not those that we furnish) pursuant to Section&#160;13(a), 13(c), 14 or 15(d) of the Exchange Act, after the date of the initial registration statement of which this prospectus is a part and prior to the effectiveness of the registration statement shall be deemed to be incorporated by reference into this prospectus and will automatically update and supersede the information in this prospectus, and any previously filed documents. All documents that we file (but not those that we furnish) pursuant to Section&#160;13(a), 13(c), 14 or 15(d) of the Exchange Act on or after the date of this prospectus and prior to the termination of the offering of any of the securities covered under this prospectus shall be deemed to be incorporated by reference into this prospectus and will automatically update and supersede the information in this prospectus, the applicable prospectus supplement and any previously filed documents. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any statement contained herein or in a document incorporated or deemed to be incorporated by reference in this prospectus or any applicable prospectus supplement shall be deemed to be modified or superseded for purposes of this prospectus and such applicable prospectus supplement to the extent that a statement contained in this prospectus or such applicable prospectus supplement, or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this prospectus and such applicable prospectus supplement, modifies or supersedes such earlier statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus or such applicable prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You can obtain any of the filings incorporated by reference into this prospectus or any applicable prospectus supplement through us or from the SEC through the SEC&#8217;s website at http://www.sec.gov. Upon request, we will provide, without charge, a copy of any or all of the reports and documents referred to above which have been incorporated by reference into this prospectus or any applicable prospectus supplement. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:468pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prospective investors may obtain documents incorporated by reference in this prospectus or any applicable prospectus supplement by requesting them in writing or by telephone from us at our executive offices at: </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Aprea Therapeutics, Inc.</font>
          <br >
          <font style="letter-spacing:0.2pt;">3805 Old Easton Road</font>
          <br >
          <font style="letter-spacing:0.2pt;">Doylestown, PA 18902</font>
          <br >
          <font style="letter-spacing:0.2pt;">(617) 463-9385 </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our reports and documents incorporated by reference herein may also be found in the &#8220;Investor Relations&#8221; section of our website at www.aprea.com. The content of our website and any information that is linked to or accessible from our website (other than our filings with the SEC that are incorporated by reference, as set forth under &#8220;Incorporation of Certain Documents by Reference&#8221;) is not incorporated by reference into this prospectus or any applicable prospectus supplement and you should not consider it a part of this prospectus, any applicable prospectus supplement, or the registration statement.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style=" width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 2.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:95.55pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Up to $1,000,000</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="position:relative;margin-top:74pt; text-align:center; width:456pt;">
          <img src="lg_apreatherapeutics-4c.jpg" alt="[MISSING IMAGE: lg_apreatherapeutics-4c.jpg]" height="93" width="418" >
        </div>
        <div style="margin-top:50.98pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Common Stock</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:71.167pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 71.1666666666667pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:12.92pt; text-align:center; width:456pt; line-height:14pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:12pt;">
          <font style="letter-spacing:-0.24pt;">PROSPECTUS</font>
        </div>
        <div style="margin-top:14.833pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 14.8333333333333pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:50.38pt; text-align:center; width:456pt; line-height:20pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:18pt;">
          <font style="letter-spacing:-0.36pt;">H.C. Wainwright &amp; Co.</font><font style="font-weight:normal;letter-spacing:0.36pt;"> </font>
        </div>
        <div style="margin-top:60pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">February&#160;2, 2024</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:122.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 122.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 2.5pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>lg_apreatherapeutics-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_apreatherapeutics-4c.jpg
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M 0,1 ?_$ +@  0 # 0$! 0$!           '" D&!00" P$! 0 # 0$!
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MXZO=, W1SXZO=, W1SXZO=, W1SXZO=, W1SXZO=, W1SXZO=, W1SXZO=,
MW1SXZO=, W1SXZO=, W1SXZO=, W1SXZO=, W1SXZO=, W1SXZO=, W1SXZO
M=, W1SXZO=, W1SXZO=,!IGD>9GE%9IF>)_VMC9/VAE,SBU;V1S6+5O=^(R,
M
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MR.Z(K-Y+C]Z,IF<6K>R.:Q:MZ0!&1@
M
M                                                 &?&MCTSU/@D
M+>$C2Y#"CBT_;\&.*$1/6#37([HBLWDN/WHRF9Q:M[(YK%JWI $9&
M
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MP2%O"1I<AA1Q:?M^#'%"(GK!IKD=T16;R7'[T93,XM6]D<UBU;T@",C
M
M                                              R-<^D7\H_?&T;=
MV>3O2M97+4#RA X9C"JW2CYG"JW2T_&29!"&MCT,U+AD+?R%AD,6.*P[?C1Q
M9\C2-.                    N=J2^CMV<-B[TL47<O=2H>Y^ZE:<5"F9\:
MV/3/4^"0MX2-+D,*.+3]OP8XH1$]8--<CNB*S>2X_>C*9G%JWLCFL6K>D 1D
M8
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MD8
M                                                    &1KGTB_E
M'[XVC;NSR=Z5K*Y:@>4('#,856Z4?,X56Z6GXR3(
M*OZZ_HA;/*3N\&+;MONG<M^V>^=RE0OF@7.U)?1V[.&Q=Z6*+N7NI4/<_=2M
M.*A3,^-;'IGJ?!(6\)&ER&%'%I^WX,<4(B>L&FN1W1%9O)<?O1E,SBU;V1S6
M+5O2 (R,
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M2 (R,
M                                                       #(USZ
M1?RC]\;1MW9Y.]*UE<M0/*$#AF,*K=*/F<*K=+3\9)D$(:V/0S4N&0M_(6&0
MQ8XK#M^-'%GR-(TX                   "YVI+Z.W9PV+O2Q1=R]U*A[G[
MJ5IQ4*9GQK8],]3X)"WA(TN0PHXM/V_!CBA$3U@TUR.Z(K-Y+C]Z,IF<6K>R
M.:Q:MZ0!&1@
M
M 9&N?2+^4?OC:-N[/)WI6LKEJ!Y0@<,QA5;I1\SA5;I:?C),@A#6QZ&:EPR%
MOY"PR&+'%8=OQHXL^1I&G3CJRY;VEF5<E:IMW1')<6'!3(CI;><8-+AO)09F
M;9I,]@Q SMZJW3$T[5=GKU5JF)IVK-=5+)7]GD\>D^&*GK[VWR5/7WMOD=5+
M)7]GD\>D^&'7WMOD=?>V^1U4LE?V>3QZ3X8=?>V^1U][;Y'52R5_9Y/'I/AA
MU][;Y'7WMOD=5+)7]GD\>D^&'7WMOD=?>V^1U4LE?V>3QZ3X8=?>V^1U][;Y
M'52R5_9Y/'I/AAU][;Y'7WMOD=5+)7]GD\>D^&'7WMOD=?>V^1U4LE?V>3QZ
M3X8=?>V^1U][;Y'52R5_9Y/'I/AAU][;Y'7WMOD=5+)7]GD\>D^&'7WMOD=?
M>V^1U4LE?V>3QZ3X8=?>V^1U][;Y(-UFLG;"RTMRB5"T8+L67-FK8D+<D.OD
M;:6C418.*41;);9"PR68KNU3%4_I89',UW:IBJ?TK,+5;KG:DOH[=G#8N]+%
M%W+W4J'N?NI6G%0IF?&MCTSU/@D+>$C2Y#"CBT_;\&.*$1/6#37([HBLWDN/
MWHRF9Q:M[(YK%JWI $9&      !\58JL.ATF=6JBO<X%.CNRY3GQ6F$&M1^X
M0]4TS5,1'[>J:9JF(C]LR:[FE?E;K51K!W#4HOC\EV249B;(;::)U9J)"$I6
M1$E)'HD1%M#5TV**8B-$-=38HIB(T1X+<ZHV84VZK1J=N5J:[-K%#DDZV_)<
M4Z\N',Q4G%2S-2M!Q+A;>P1I(4O<+,451,:I4?<+,45Q5$?B5BA6*L  %)M;
M>Y[FHV9L*+1ZU/I\55(CN*8B2GF&S6;\@C5HMJ26)D1;(O\ (44U6_S$:V@[
M?135;_,1/Y0+Y_WWSHJ_'Y/W@L?BHV1X++X:.6/ \_[[YT5?C\G[P/BHV1X'
MPT<L>!Y_7WSHJW'Y/W@?%1LCP/AHY8\%E-7/6/=0ZQ8>8L]3C;BB;HM=E+-2
MDJ4>PQ)<4>)I,_HW%;7\IGAAA59S)_\ NB-\*G.9+_W1&^%OQ2*, 4TUP;DN
M.B7W0V*-6)U.8<I*5N-1)+S"%+\9>+2-+:DD9X$18B][?1351.F(G\K[MU%-
M5$Z8B?RKOY_WWSHJ_'Y/W@L_BHV1X+3X:.6/ \_[[YT5?C\G[P/BHV1X'PT<
ML>!Y_7WSHJ_'Y/W@?%1LCP/AHY8\%A]7;60?ITAJR,QZ@MZFOK)-)KLM9K7'
M<6?T4AQ1F9MJ,_@K4?P#V#^!_)69S)Z?^J(X*O.9+3_U1'YV+ED9*(E)/%)[
M)&6T9"B4+_0'&YMR9,/*^\)<-Y<>4Q2)KC+[*C;<0M+*C)25),C(R/LD.^7C
M3<IWN^7C3<IT[89O>?U]\Z*MQ^3]X-3\5&R/!J_AHY8\#S_OOG15^/R?O ^*
MC9'@?#1RQX'G_??.BK\?D_>!\5&R/ ^&CECP//\ OOG15^/R?O ^*C9'@?#1
MRQX-$LC9DJ?E+:<R;(<E2WH)*>D/+4ZXM6FHL5*49F9^V,QFHB+M41M9?-1$
M7:HC:D$1D4  &?6L!FQ<=8S2K+-OUN;!HU(45+C-PI3K#:E1<2>69-J(C,W3
M7\+XI$-+E+%,6XTQ^9_+393+TQ;C3$:9_+L-4W-"M+ON7:=QU:54&*[&-4$Y
MLAR0:)<,C<(D&XI6&FV;F.&V:4CAG[$>CU1&IP[A8CT>JF-&A=44*@
M                                                       &1KGT
MB_E'[XVC;NSR=Z5K*Y:@>4('#,856Z4?,X56Z6GXR3((0UL>AFI<,A;^0L,A
MBQQ6';\:.+/D:1IUG=2GTTN3DM'E"!4]R]D;U1W/V1O78%"SX
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M]MI]!+2?N&,A53-,S$_ICJJ9IF8G]/M'EY
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M5=PM^FYIYE3W"UZ;GJYE@16JP
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M*F>Y4Q_YE43W.F/_ #+^G4FNGG33_L'@^RIY9?/LZ>67VTC4SN>FU:!457/
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M%-N-LZ6^1G\$GUF2XZL.WNB2;+Y9B1GK?KMZ?W'Y2<_:]=K3^X_+0D9IF
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MYU"=I#^&B\C_ ,#A*3_ 9&[;]%<T[&.NV_17-.QT8Y.0
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MA'&D&2'B27:0X25'[+@KNXVM$Q7M5_<K6BJ*]OX6G%0I@
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M21X; 35,ZY)KF=<OO'EY
M                  !D:Y](OY1^^-HV[L\G>E:RN6H'E"!PS&%5NE'S.%5N
MEI^,DR"$-;'H9J7#(6_D+#(8L<5AV_&CBSY&D:=9W4I]-+DY+1Y0@5/<O9&]
M4=S]D;UV!0L^CS,/.JQLL*A$IEU.R6Y4UDY+!1XZGDFV2C1LF1D1'B6T)-G+
M5W8TTI5G+5W8TTN-ZW&3O^ZJ'$U]T=_K[O\ 3O\ 7W?Z2C8U\4',.@-W+;:W
M5TMUQQE"GVS97IM'@KX)]C$1+MJJW5Z:M:'=M56ZO35K=(.3DS"SEZ6+TY9G
M;^H:W+85.Z&ORV%3NAPX[I#6NF_IT3ZEOO"&,JUL35K<AG-T37IR/-WE0[Y;
M%IWN^6Q:=\,PQK&O3/JJ]-E#^HG>2.B#GL&>"!G\&>'^M#AF675?UU_1"V>4
MG=X,6W;?=.Y;]L]\[E*A?- N=J2^CMV<-B[TL47<O=2H>Y^ZE:<5"F9\:V/3
M/4^"0MX2-+D,*.+3]OP8XH1$]8--<CNB*S>2X_>C*9G%JWLCFL6K>D 1D8
M
M                                                &1KGTB_E'[XV
MC;NSR=Z5K*Y:@>4('#,856Z4?,X56Z6GXR3((0UL>AFI<,A;^0L,ABQQ6';\
M:.+/D:1IUG=2GTTN3DM'E"!4]R]D;U1W/V1O78%"SZE.NOZ7VSR:YOZA?=M]
ML[V@[9[)WJP"V6[035+Z&H'#9N^C-Y_%G<S/<,:=T)Q%>KF86<O2Q>G+,[?U
M#6Y;"IW0U^6PJ=T.''=(:UTW].B?4M]X0QE6MB:M;D,YNB:].1YN\J'?+8M.
M]WRV+3OAF&-8UZ9]57ILH?U$[R1T0<]@SP0,_@SP_P!:'#,LNJ_KK^B%L\I.
M[P8MNV^Z=RW[9[YW*5"^:!<[4E]';LX;%WI8HNY>ZE0]S]U*TXJ%,SXUL>F>
MI\$A;PD:7(84<6G[?@QQ0B)ZP::Y'=$5F\EQ^]&4S.+5O9'-8M6]( C(P
M
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M:]*M:(^N3&I,=$5I]TB)Q:6RP(U$G L16W*_75-6U67*_75-6U[8YN8
M *'ZY'2M#Y&C;_(&B[=A<6C[;A<74:D?ZO>/!H.^/#CW/53Q<>YZJ>*Y HU$
M  "A6N)TM,<D1=]?&B[=A<6D[=A<7RZMF;MIY42;C>NE,M2:HW$1%\3:2]LQ
MU/&O2TEHP_G3@/6<R]5W1Z?T]9W+U7='I_2P'7#RE_RJOQ1O[X5OU]W^E9]=
M=_HZX>4O^55N*-_?!]?=_H^NN_TH?,=2_+?>1CH..+6G';P4HS+$:*-31QJ:
M0ZO'0O:/!7/*'1ELWBU,IG,:I)PB(B ]<#HC+E6)WKHL>WXO!9=NQ>"EV7-P
MP;3ONWKEJ:7%T^ESF94E+"24Z;;:L3T24:2,_P")"^O4371-,?N%_>HFNB:8
M_<+D]<C*C_9UKBL?\R*/ZZ[_ $H?K;O]'7(RH_V=:XK'_,A]==_H^MN_TZ&Q
M]9;+[,"YX5IT.-5&ZG/W7<5RH[2&2W%I3JM)2'EF7P4'A\';'*[DJ[=/JG1H
M<[N2N6Z9JG1H3&(*  *H:[OZ79O")_>,"Y[9KJX+KMFNK@AW5?JM+HN;<&?6
M)T>G041)B529;J&&B4IHR(C6X:2Q/L;(FYZF:K4Q$:4[/4S5:F(C2O5ZR,N^
M=U%_Y*)]X,_\-SEGP9WX;G+/@^&LYNY9T.ERJM*NFF/L1&S<4S$F,29"\-I+
M;3:S4I1GL$1>\/5.7N53H],O5.7N53H],LQYSZ)4V3)01DAYU;B25MD2U&98
MX>V-7$:(:Z(T0THR%2I.3MG$I)I/^WH/ R,CP-2C(]GMELD,MFL6K>R>;Q:M
MZ11%10!&6?\ >GF/E97*BRYN=2G-_P!KIQD>"MWF$:#4GV4-Z;A?)$O*6_7<
MB.*7E+7R78C]:U",JK15?.8=OVR:#7&F2T*FEA_\1C%U_P#_ !H41>R-%?N>
MBW-32YBY\=N:EAM=&S";7;U]Q&B2@TJHT\TE@1:.D]'/8]C=2_@1"M[;<UT\
M57VV[KHG>\;4SO3^W715K'E.81ZRP4V"DSV/&H9'II27;6T9J/ZL>^XV]-,5
M;'3N5K33%6Q=<4+/@  R4J?ZE,^O=[\QLZ=3:TZFD>0/0W9_ 2WQ8RV;Q:M[
M*YO%JWI($5$5*UW)<4XUG02>0<U#DYY4<E$;A-+)E*5FG;))FDR(^S@?:%SV
MR)TU3N7?;(G35.Y&VJ+TP,\G3/>0)?<,+BE=PPN*_P ,VS0 S?UDNFV[/KHW
MD; U&3P:?Y^VJR6#3_/V[K5VSWLO*JUZI1[E8J#LN;/.6TJ$RTZC<]Q;;P,U
MNMF1XI/L"/G,K7=JB:=&I'SF5KNU1-.C4F+KD94?[.M<5C_F1"^NN_T@?6W?
MZ.N1E1_LZUQ6/^9#ZZ[_ $?6W?Z2YE_?E&S(MMFZ: W(:IK[CK*$2T);=TF5
M&A6)(6LL,2V/A"%=M3;J],H5ZU-JKTSK=0.+B ,K+_\ 3NZ.5Y_E+@V%KV1N
MALK/LIW0O=JK]"5!^MG>6.C.Y[&GA_C.9_&GA_B91!0$7ZQ70M=W!FO*6A+R
M>-2F9/&I9UV_^O4OA<??4C3U^V6HK]LM9!C6+  !Y-T>C-9X#*WE0]T>Z-[W
M;]T;V4 V+:-3,L^C>SN0Z9Y(T,C>Q*M\L=?Q*M\_ZZD<7$  &7N;G2E>G+=0
M\I6-;E\.G=#7Y?"IW0NAJE=#<'ATW?119_%X*'N&-.Z$Y"O5P R?N?TEK/#I
M._*&QH]L;FTH]L;FAFK=T)VG]3)\L?&:SF-5_/TR^=QJOY^DJ"&AOYR(\>4R
MJ/*:0^PO^=IU)+0K \=DE8D>R/L3H?8G0^)-OT%*B6FEQ"4DR4E11VB,C(\2
M,O@]@??75M>O75M>B/+P ,U,^K;K=O9JW*JL0UQFZI/DU&GNGLMOQ9#REH6A
M1;![!X*+_"K$C&JRM<56XT?J&LRE<56HT?J$A9&ZRU/RSM5RTKAI#\V&P\M^
MGR8!H)S^NHU.(=)Q22/ ]E*B/V,!&S62F[5ZHE%S62F[5ZHE*'75L3F]5_PW
MWHB?6U[80_K*]L/ZQ]='+]V0TV_0ZLPRM:4N/FF.HD),\#5HI=Q/#;P(?)[;
M7M@GMMS;"?/.NV_-OSP_N<?S9\7\<_NFF6X;AACI8_\ 3#;QV,,16_'5ZO3H
M_*M^.KU>G1^64KGTB_E'[XV+9NSR=Z5K*Y:@>4('#,856Z4?,X56Z6GXR3(
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MB ]<#HC+E6)WKHL>WXO!9=NQ>"CMK6[-NVXJ9;-.6TU/JLAN)'<?-26DK=/
MC6:4J,B]I)C05UQ13-4_IH;E<44S5/Z3KU,<S_W6A_;RORHK_L;>R?YQ5WV5
MO9/\XG4QS/\ W6A_;RORH?8V]D_SB?96]D_SB[O)O5EOO+W,2D7;6:A2GZ=
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MG?SG_ P/RX=%9V><G0V>7SDZSV=_.?\  P/RX=%9V><G0V>7SDZSV=_.?\#
M_+AT5G9YR=#9Y?.3K/9W\Y_P,#\N'16=GG)T-GE\Y.L]G?SG_ P/RX=%9V><
MG0V>7SDZSV=_.?\  P/RX=%9V><G0V>7SDZSV=_.?\# _+AT5G9YR=#9Y?.3
MK/9W\Y_P,#\N'16=GG)T-GE\Y.L]G?SG_ P/RX=%9V><G0V>7SDZSV=_.?\
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MC_N=RE*/Y5_)_P#,0OF@?XX9&XHRVL3]\!^0
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M$:52U)/%+[I;9,D>RA/_ *FW_)_/5YS.>G_BG7^U5G<YZ?\ BC7^UU!0J
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IJ=<,K'/I%^V?OC7MD_ #I,OO3RV>5(6_H'*[[)W.5[V5;I:?#)L@_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
